Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20;21(2):555-563.
doi: 10.5114/aoms/148209. eCollection 2025.

Efficacy and safety of apixaban and warfarin in prevention of ischemic stroke: a systematic review and meta-analysis

Wei Gu  1 , Jianghong Luo  2 , Fang Zhang  1 , Jiankun Hong  1 , Jianping Chen  3 , Ying Huang  4   5   6 , Wei Xie  1
Affiliations
Review

Efficacy and safety of apixaban and warfarin in prevention of ischemic stroke: a systematic review and meta-analysis

Wei Gu et al. Arch Med Sci. .

Abstract

Introduction: Due to various limitations of warfarin use, non-vitamin K oral anticoagulants have gradually become the first choice for the prevention of ischemic stroke. This article will comprehensively and systematically evaluate the efficacy and safety of apixaban and warfarin in the prevention of ischemic stroke, to provide an evidence-based reference for clinical diagnosis and treatment.

Material and methods: A comprehensive search of electronic databases, including PubMed, Embase, Cochrane Library, Web of Science, Clinical Trials, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and Wanfang Database, was performed, and the cut-off date for all databases was May 31, 2021. We reviewed a large number of studies on apixaban versus warfarin in the prevention of ischemic stroke. We compared the incidence of ischemic stroke, any other thromboembolic events, major bleeding, intracranial hemorrhage, and gastrointestinal hemorrhage.

Results: From the initial search of 288 results, the final meta-analysis included 11 studies, comprising 6 retrospective cohort studies, 4 observational studies, and 1 randomized controlled trial, with a total of 240,652 patients. There was no statistically significant difference between apixaban and warfarin in incidence of ischemic stroke (OR = 0.80, 95% CI: (0.56, 1.16), p = 0.25) and thromboembolic events (OR = 0.83, 95% CI: (0.63, 1.10), p = 0.19). In the apixaban group, major bleeding (OR = 0.68, 95% CI (0.55, 0.84), p = 0.0003), intracranial hemorrhage (OR = 0.48, 95% CI (0.42, 0.56), p < 0.00001), and gastrointestinal hemorrhage (OR = 0.66, 95% CI (0.60, 0.72), p < 0.00001) were significantly lower than in the warfarin group.

Conclusions: Apixaban has more advantages and a higher safety profile than warfarin, making it worthy of widespread use.

Keywords: apixaban; ischemic stroke; major bleeding; meta-analysis; warfarin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart diagram of the study selection
Figure 2
Figure 2
Incidence of ischemic stroke
Figure 3
Figure 3
Incidence of any thromboembolic event
Figure 4
Figure 4
Incidence of major bleeding
Figure 5
Figure 5
Incidence of intracranial hemorrhage
Figure 6
Figure 6
Incidence of gastrointestinal hemorrhage
Figure 7
Figure 7
Incidence of ischemic stroke after exclusion
Figure 8
Figure 8
Funnel plot of intracranial hemorrhage
See this image and copyright information in PMC

References

    1. Virani SAA, Aparicio H, Benjamin E, et al. 2021 Heart Disease and Stroke Statistics Update Fact Sheet At-a-Glance. J Am Heart Assoc 2021; 6: 5-7.
    1. Seeger J, Wohrle J. Apixaban: an update of the evidence for its place in the prevention of stroke in patients with atrial fibrillation. Core Evid 2020; 15: 1-6. - PMC - PubMed
    1. Wańkowicz P, Nowacki P, Gołąb-Janowska M. Atrial fibrillation risk factors in patients with ischemic stroke. Arch Med Sci 2021; 17: 19-24. - PMC - PubMed
    1. Wańkowicz P, Nowacki P, Gołąb-Janowska M. Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range. Arch Med Sci 2019; 15: 1217-22. - PMC - PubMed
    1. Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017; 17: 238. - PMC - PubMed

LinkOut - more resources